Mitochondria Localized Anticancer Iridium(III) Prodrugs for Targeted Delivery of Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors and Cytotoxic Iridium(III) Complex
Inorganic Chemistry · 30.12.2024 · 63 (52) · 24709-24723
DOI: 10.1021/acs.inorgchem.4c03950 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inorganic Chemistry, online erschienen am 12.12.2024. Verfasst von Tejal Dixit und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Indian Institute of Technology Roorkee, Roorkee, Uttarakhand 247667, India. Hauptthemen laut MEDLINE: Iridium, Prodrugs, Antineoplastic Agents, Myeloid Cell Leukemia Sequence 1 Protein. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 107 Literaturangaben. Gefördert von: University Grants Commission, Indian Institute of Technology Roorkee.
Abstract (Originalsprache)
Myeloid cell leukemia-1 (Mcl-1) is an antiapoptotic oncoprotein overexpressed in several malignancies and acts as one of the promising therapeutic targets for cancer. Even though there are several small molecule based Mcl-1 inhibitors reported, the delivery of Mcl-1 inhibitor at the target site is quite challenging. In this regard, we developed a series of mitochondria targeting luminescent cyclometalated iridium(III) prodrugs bearing Mcl-1 inhibitors via ester linkage due to the presence of Mcl-1 protein in the outer mitochondrial membrane. Among the synthesized prodrugs, IrThpy@L2 was found to exhibit the potent cytotoxicity (IC50 = 30.93 nM) against HCT116 cell line when compared with bare Mcl-1 inhibitors (IC50 > 100 μM). Mechanistic studies further revealed that IrThpy@L2 quickly gets internalized inside the mitochondria of HCT116 cells and undergoes activation in the presence of overexpressed esterase which leads to the release of two cytotoxic species i.e. Mcl-1 inhibitors (I-2) and cytotoxic iridium(III) complex (IrThpy@OH). The improved cytotoxicity of IrThpy@L2 is due to the mitochondria targeting ability of iridium(III) prodrug, subsequent esterase activated release of I-2 to inhibit Mcl-1 protein and IrThpy@OH to generate reactive oxygen species (ROS). After prodrug activation, the released cytotoxic species cause mitochondrial membrane depolarization, activate a cascade of mitochondria-mediated cell death events, and arrest the cell cycle in S-phase which leads to apoptosis. The potent anticancer activity of IrThpy@L2 was further evident from the drastic morphological changes, size reduction in the solid tumor mimicking 3D multicellular tumor spheroids (MCTS) of HCT116.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Indian Institute of Technology Roorkee, Roorkee, Uttarakhand 247667, India.
ORCID-Profile: V Venkatesh
Förderung
- University Grants Commission
- Indian Institute of Technology Roorkee
Zitieren
APA
Dixit, T., Negi, M., & Venkatesh, V. (2024). Mitochondria Localized Anticancer Iridium(III) Prodrugs for Targeted Delivery of Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors and Cytotoxic Iridium(III) Complex. Inorganic Chemistry, 63(52), 24709-24723. https://doi.org/10.1021/acs.inorgchem.4c03950
Vancouver
Dixit T, Negi M, Venkatesh V. Mitochondria Localized Anticancer Iridium(III) Prodrugs for Targeted Delivery of Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors and Cytotoxic Iridium(III) Complex. Inorganic Chemistry. 2024;63(52):24709-24723. doi:10.1021/acs.inorgchem.4c03950
BibTeX
@article{Dixit2024,
author = {Dixit, Tejal and Negi, Monika and Venkatesh, V},
title = {Mitochondria Localized Anticancer Iridium(III) Prodrugs for Targeted Delivery of Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors and Cytotoxic Iridium(III) Complex},
journal = {Inorganic Chemistry},
year = {2024},
volume = {63},
number = {52},
pages = {24709--24723},
doi = {10.1021/acs.inorgchem.4c03950}
}
EUVIMED